GlassScriptPhysician profile
Sean M Cunningham
NPI 1023469590
$1,336.92
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $593 · 2021: $63.38 · 2022: $24.19 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $393.53 | 2019-2021 | |
| Pfizer INC. | $132.24 | 2019-2020 | |
| Edwards Lifesciences Corporation | $124.62 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novo Nordisk INC | $112.98 | 2019-2022 | |
| Amgen INC. | $78.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $68.31 | 2019-2020 | |
| Glaxosmithkline, LLC. | $45.89 | 2019-2020 | |
| Lilly USA, LLC | $45.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.53 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $36.16 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.47 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.70 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $23.81 | 2020 | |
| Astellas Pharma US INC | $18.16 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.77 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $16.67 | 2019 | |
| Indivior INC. | $16.53 | 2019 | |
| Merck Sharp & Dohme LLC | $15.93 | 2020 | |
| Mylan Specialty L.P. | $15.86 | 2019 | |
| Esperion Therapeutics, INC. | $15.12 | 2020 | |
| Neurocrine Biosciences, INC. | $14.11 | 2019 | |
| Genentech USA, INC. | $13.91 | 2020 | |
| Ibsa Pharma INC. | $12.02 | 2020 | |
| Allergan, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.